Siemens displays SmartLight viewer in ECR boothIsraeli motorized light box developer SmartLight has received a big vote of confidence in its technology after signing a distribution agreement covering Germany with Siemens Medical Engineering Group
Siemens displays SmartLight viewer in ECR booth
Israeli motorized light box developer SmartLight has received a big vote of confidence in its technology after signing a distribution agreement covering Germany with Siemens Medical Engineering Group of Erlangen. The deal gives a boost to SmartLights distribution efforts in Germany, and could be expanded to other markets, according to SmartLight executives.
The agreement is the outgrowth of a relationship that began in 1998 between SmartLight and Siemens covering Scandinavia, according to Arie Dan, vice president of sales for Nesher-based SmartLight. Siemens decided to extend the relationship to the large German market because of preliminary results from studies indicating that SmartLights technology can result in a 30% to 40% increase in visualization of x-ray films.
SmartLights viewers are based on a computer-controlled system that automatically senses which areas of the light box are needed for viewing and masks areas that arent required for illumination. The end result is that films displayed on SmartLight viewers seem sharper because of the reduction of ambient glare. The technology has received enthusiastic reviews from many radiologists, but some industry observers have been skeptical of SmartLights prospects because of the high cost of the viewers relative to conventional light boxes.
Siemens is convinced of the usefulness of SmartLights viewers and believes they are a revolutionary technology, according to Roselle Anderson, market manager of womens health for the German vendor. The relationship gives Siemens access to a unique product that it can use to differentiate itself from other vendors, particularly in the mammography market, she said. Siemens displayed a SmartLight 2000 viewer in the mammography section of its booth at last months European Congress of Radiology in Vienna.
The German market is a good one for SmartLights technology, due to the countrys recently enacted DIN 6856 rules covering film viewing, which require film masking, variable light intensities, and other features that SmartLights viewers provide automatically. The rules are forcing many German hospitals to completely replace their light box inventories, according to Jerry Arenson, a former Elscint executive who is SmartLights vice president of marketing.
SmartLight will continue to maintain its direct sales presence in Germany, and its subsidiary there will work with Siemens, Arenson said. SmartLight also hopes to extend the deal to other countries, and is in discussions with other imaging vendors about potential relationships. SmartLight already has distribution agreements with Fuji in Japan and with Hologic in France.
The Siemens relationship comes as SmartLight is beginning deliveries of a motorized version of its film viewer, which was introduced at the 1997 RSNA meeting (SCAN 1/21/98). The company believes the new product will help it achieve revenues of $10 million in 1999, compared with $2.6 million in 1998 and $1 million in 1997.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.